CLDN18
ENSG00000066405
Target class
Unclassified protein
Chromosome
3
Approved drugs
1
Clinical candidates (approved and in development)
1
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- No
- Target name
- CLDN18
- Gene name
- Claudin 18
- Gene symbol
- CLDN18
- Previous gene symbols
- SFTPJ
- Protein name
- Claudin-18
- Gene biotype
- Protein coding
- Gene family
- Claudins
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 6
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 391.23
- Tissue specificity (Gini)
- 0.949
- Tissue specificity (tau)
- 0.992
- KEGG gene identifiers
- hsa:51208
- Reactome pathways
- R-HSA-420029
- Protein interaction confidence
- 0.756474
- Protein interaction partners
- 19
- End position
- 138033655
- Start position
- 137998735
- Chromosome
- 3
- Strand
- Forward
- Cell junction, tight junction . Cell membrane
- Multi-pass membrane protein . Note=Localizes to tight junctions in epithelial cells. .
- SUBCELLULAR LOCATION: [Isoform A1]: Cell junction, tight junction .
- SUBCELLULAR LOCATION: [Isoform A2]: Cell junction, tight junction . Lateral cell membrane .
- Cell Junctions
- Tissue specificity (tau)
- 0.992146
- Expression inequality (Gini)
- 0.948958
Expression in transcripts per million
- Stomach
- 391.23
- Lung
- 140.5
- Testis
- 2.3
- Ovary
- 1.06
- Uterus
- 1.05
Expression in transcripts per million
- Stomach391.23
- Lung140.5
- Testis2.3
- Ovary1.06
- Uterus1.05
- Cervix - Ectocervix1.04
- Fallopian Tube0.98
- Cervix - Endocervix0.96
- Artery - Aorta0.83
- Pituitary0.75
- Bladder0.7
- Brain - Cerebellum0.68
- Nerve - Tibial0.68
- Vagina0.66
- Artery - Tibial0.63
- Artery - Coronary0.62
- Cells - Cultured fibroblasts0.54
- Esophagus - Gastroesophageal Junction0.53
- Prostate0.52
- Heart - Atrial Appendage0.52
- Colon - Sigmoid0.48
- Esophagus - Muscularis0.47
- Thyroid0.46
- Brain - Cerebellar Hemisphere0.45
- Kidney - Medulla0.42
And 29 more, listed on the interactive page.
Molecular functions
- GO:0005515
Related records
Trials (22)
- A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
- A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer
- A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
- A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer
- A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
- A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
- A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer
- A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
- A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.
- AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas
- Early Access Program for Zolbetuximab
- Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer
- Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer
- Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
- Phase Ib/IIa Open-label Study, to Evaluate Safety, Tolerability, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Gastric or Gastro-esophageal (GEJ) Adenocarcinoma
- Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer
- Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer
- Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer
- Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Drugs (1)
- Zolbetuximab Claudin-18 binding agent